CO6270232A2 - Derivados de catecolamina utiles para el tratamiento de enfermedades de parkinson - Google Patents

Derivados de catecolamina utiles para el tratamiento de enfermedades de parkinson

Info

Publication number
CO6270232A2
CO6270232A2 CO09149335A CO09149335A CO6270232A2 CO 6270232 A2 CO6270232 A2 CO 6270232A2 CO 09149335 A CO09149335 A CO 09149335A CO 09149335 A CO09149335 A CO 09149335A CO 6270232 A2 CO6270232 A2 CO 6270232A2
Authority
CO
Colombia
Prior art keywords
group
compound according
catecolamine
derivatives
useful
Prior art date
Application number
CO09149335A
Other languages
English (en)
Inventor
Morten Jorgensen
Benny Bang-Andersen
Ask Puschl
Niels Mork
Jennifer Larsen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39877715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6270232(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CO6270232A2 publication Critical patent/CO6270232A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Portable Nailing Machines And Staplers (AREA)
  • Indole Compounds (AREA)

Abstract

1.- Un compuesto que tiene la estructura I° en donde n = 0, 1° en donde R1 y R2 se fusionan y forman un grupo metileno (CH2), un grupo carbonilo (C=O), o un grupo oxalilo (O=C-C=O)° R3 se selecciona del grupo que consiste de hidrogeno, metilo, etilo, n-propilo, ciclo-propilo, ciclo-butilo, alilo, propargilo, hidroxietilo, 3-fluoropropilo y 2-fluoroetilo, y sales de adicion acida farmacéuticamente aceptables de los mismos. 2.- El compuesto de acuerdo con la Reivindicacion 1 en donde R3 se selecciona del grupo que consiste de hidrogeno, metilo, etilo, n-propilo, alilo, y propargilo, tal como metilo y n-propilo. 3.- El compuesto de acuerdo con una cualquiera de las reivindicaciones precedentes en donde R3 se selecciona del grupo que consiste de ciclo-propilo, ciclo-butilo, e hidroxietilo. 4.- El compuesto de acuerdo con una cualquiera de las reivindicaciones precedentes en donde n = 0. 5.- El compuesto de acuerdo con una cualquiera de las reivindicaciones 1-3 en donde n = 1. 6.- El compuesto de acuerdo con una cualquiera de las reivindicaciones precedentes caracterizado adicionalmente por ser el trans-diastereoisomero sustancialmente puro.
CO09149335A 2007-08-31 2009-12-30 Derivados de catecolamina utiles para el tratamiento de enfermedades de parkinson CO6270232A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200701250 2007-08-31

Publications (1)

Publication Number Publication Date
CO6270232A2 true CO6270232A2 (es) 2011-04-20

Family

ID=39877715

Family Applications (2)

Application Number Title Priority Date Filing Date
CO09149335A CO6270232A2 (es) 2007-08-31 2009-12-30 Derivados de catecolamina utiles para el tratamiento de enfermedades de parkinson
CO10023455A CO6260082A2 (es) 2007-08-31 2010-02-26 Derivados de catecolamina utiles para el tratamiento de enfermedad de parkinson

Family Applications After (1)

Application Number Title Priority Date Filing Date
CO10023455A CO6260082A2 (es) 2007-08-31 2010-02-26 Derivados de catecolamina utiles para el tratamiento de enfermedad de parkinson

Country Status (29)

Country Link
EP (4) EP2197883B1 (es)
JP (4) JP2010536890A (es)
KR (3) KR20100051834A (es)
CN (3) CN101687878A (es)
AR (2) AR068045A1 (es)
AU (2) AU2008291425B2 (es)
BR (2) BRPI0813456A2 (es)
CA (2) CA2691961C (es)
CL (2) CL2008002558A1 (es)
CO (2) CO6270232A2 (es)
CY (1) CY1117326T1 (es)
DK (1) DK2197883T3 (es)
EA (2) EA018413B1 (es)
ES (1) ES2557485T3 (es)
HR (1) HRP20151334T1 (es)
HU (1) HUE025882T2 (es)
IL (1) IL203080A (es)
MX (1) MX2010002210A (es)
MY (2) MY148948A (es)
NZ (2) NZ583551A (es)
PL (1) PL2197883T3 (es)
PT (1) PT2197883E (es)
RS (1) RS54470B1 (es)
SG (1) SG184711A1 (es)
SI (1) SI2197883T1 (es)
TW (2) TWI404702B (es)
UA (2) UA97989C2 (es)
WO (2) WO2009026935A1 (es)
ZA (2) ZA200909191B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
JP2011525893A (ja) * 2008-06-27 2011-09-29 ハー・ルンドベック・アクチエゼルスカベット 新規のフェノールアミン類およびカテコールアミン類ならびにそのプロドラッグ
US8067410B2 (en) 2008-06-27 2011-11-29 H. Lundbeck A/S Phenolic and catecholic amines and prodrugs thereof
TW201035054A (en) * 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
BR112019014981A2 (pt) 2017-11-24 2020-04-07 H Lundbeck As composto, sal farmaceuticamente aceitável, uso dos mesmos e composição farmacêutica
WO2020070099A1 (en) 2018-10-02 2020-04-09 H. Lundbeck A/S Administration of catecholamine prodrugs in combination with a 5-ht2b antagonist
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) * 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) * 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US20220220077A1 (en) 2019-05-21 2022-07-14 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP7514859B2 (ja) 2019-05-21 2024-07-11 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
EP3972970A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP2022533914A (ja) * 2019-05-21 2022-07-27 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するためのカテコールアミンカルバメートプロドラッグ
JP2023552699A (ja) 2020-11-17 2023-12-19 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
CN113620760A (zh) * 2021-09-07 2021-11-09 张家口思睿凯科技有限公司 一种电子盐反应液和不饱和芳香烃类化合物的还原方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) * 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
CH648300A5 (en) * 1979-06-22 1985-03-15 Sandoz Ag Phenanthrene derivatives and medicaments containing them
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
WO1990012574A1 (en) * 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
DD299303A5 (de) * 1989-08-30 1992-04-09 ��@���������@�������k�� Indolobenzoquinolinderivate, deren herstellung und verwendung als antiarrhythmische medikamente
TW357143B (en) * 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
WO1997017326A1 (en) * 1995-11-10 1997-05-15 Novo Nordisk A/S Enantiomers of cis-benz[e]indole compounds, their preparation and utility as dopamine-d3 receptor selective agents
CN1241998A (zh) * 1996-10-30 2000-01-19 伊莱利利公司 苯并[f]喹啉酮的合成
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
AR030357A1 (es) * 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥

Also Published As

Publication number Publication date
EA201070327A1 (ru) 2010-08-30
EP2662358A1 (en) 2013-11-13
CL2008002564A1 (es) 2009-07-17
CN107253956A (zh) 2017-10-17
JP2014111635A (ja) 2014-06-19
TWI404702B (zh) 2013-08-11
WO2009026934A1 (en) 2009-03-05
AR068045A1 (es) 2009-10-28
PT2197883E (pt) 2016-02-02
HRP20151334T1 (hr) 2016-01-01
KR20150115963A (ko) 2015-10-14
DK2197883T3 (en) 2016-01-11
AU2008291425A1 (en) 2009-03-05
MX2010002210A (es) 2010-03-17
ZA201001422B (en) 2011-06-29
ZA200909191B (en) 2011-03-30
JP2014148528A (ja) 2014-08-21
EP2195291A1 (en) 2010-06-16
CA2691961C (en) 2013-12-17
RS54470B1 (en) 2016-06-30
CN101687878A (zh) 2010-03-31
BRPI0813456A2 (pt) 2014-12-23
MY148948A (en) 2013-06-14
HUE025882T2 (en) 2016-04-28
CA2691961A1 (en) 2009-03-05
KR20100046111A (ko) 2010-05-06
KR20100051834A (ko) 2010-05-18
IL203080A (en) 2014-11-30
EP2197883B1 (en) 2015-11-18
CN101842354A (zh) 2010-09-22
EA018011B1 (ru) 2013-04-30
UA98804C2 (ru) 2012-06-25
EP2197883A1 (en) 2010-06-23
AU2008291426A1 (en) 2009-03-05
AU2008291426B2 (en) 2013-01-31
NZ582379A (en) 2011-08-26
NZ583551A (en) 2012-07-27
CO6260082A2 (es) 2011-03-22
JP2010536889A (ja) 2010-12-02
EP3009437A1 (en) 2016-04-20
CL2008002558A1 (es) 2009-08-07
JP5548125B2 (ja) 2014-07-16
EA200971107A1 (ru) 2010-06-30
SI2197883T1 (sl) 2016-01-29
EA018413B1 (ru) 2013-07-30
TW200911752A (en) 2009-03-16
JP2010536890A (ja) 2010-12-02
CA2697688A1 (en) 2009-03-05
CY1117326T1 (el) 2017-04-26
AU2008291425B2 (en) 2012-12-06
ES2557485T3 (es) 2016-01-26
AR068044A1 (es) 2009-10-28
BRPI0815894A2 (pt) 2015-02-24
WO2009026935A1 (en) 2009-03-05
PL2197883T3 (pl) 2016-03-31
MY179527A (en) 2020-11-10
TW200914426A (en) 2009-04-01
JP5802792B2 (ja) 2015-11-04
KR101597367B1 (ko) 2016-02-24
UA97989C2 (uk) 2012-04-10
SG184711A1 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
CO6270232A2 (es) Derivados de catecolamina utiles para el tratamiento de enfermedades de parkinson
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
AR112774A1 (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona
AR087301A1 (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide
CO7111284A2 (es) Nucleósidos de espirooxetano de uracilo
AR068051A1 (es) Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer.
UY31612A1 (es) Derivados de incol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparación y su aplicación en terapéutica
AR092835A1 (es) Compuestos de d-aminoacido para enfermedades del higado
AR060545A1 (es) Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas
UY30842A1 (es) Derivados de n-(amino-heteroaril)-1h-pirrolopiridin-2-carboxamidas, su preparacion y su aplicacion en terapéutica
AR066130A1 (es) Formas cristalinas de saxagliptina y procesos para preparar las mismas
AR065880A1 (es) Derivados fluorinados de deferiprona
AR106515A1 (es) Sililfenoxiheterociclos trisustituidos y análogos
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CO6660514A2 (es) Derivados de ácido 2 quinolinil acético como compuestos antivirales del vih
CO6260076A2 (es) Derivados de uracilo o timina para el tratamiento de la hepatitis c
UY31608A1 (es) Derivados de carboxamidas n-azabicíclicas, su preparación y su aplicación en terapéutica
AR072233A1 (es) Derivados de acido lipoico y composiciones farmaceuticas que los contienen y metodos para tratar una enfermedad
EA201270216A1 (ru) Фармацевтический состав
PE20091843A1 (es) Inhibidores de catepsina c
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
AR087302A1 (es) Derivados aza heterociclicos sustituidos
UY37764A (es) Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)

Legal Events

Date Code Title Description
FG Application granted